Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

被引：0

作者：

Tavara, B. ^{[1
]}

Garrido, M. L. ^{[1
]}

Rodriguez, Z. ^{[1
]}

Rojas, M. ^{[1
]}

Lopez, L. ^{[1
]}

Medina, S. ^{[1
]}

Ponte, C. ^{[1
]}

Lopez, A. ^{[1
]}

Sanchez, E. ^{[1
]}

Pedraza, M. ^{[1
]}

Vinals, P. ^{[1
]}

Lopez, M. ^{[1
]}

Alonso, D. ^{[1
]}

Rodriguez, A. ^{[1
]}

Davila, E. ^{[1
]}

Castanon, C. ^{[1
]}

De Sande, L. M. ^{[1
]}

Nieto, B. ^{[1
]}

Vallejo Pascual, M. E. ^{[2
]}

Rodriguez, J. D. L. R. ^{[1
]}

Garcia Palomo, A. ^{[1
]}

Diz Tain, P. ^{[1
]}

机构：

[1] Complejo Asistencial Univ Leon, Leon, Spain

[2] Univ Leon, Leon, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

DURVALUMAB; PACIFIC; REAL WORLD DATA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP05.02-0

引用

页码：S283 / S283

页数：1

共 50 条

[1] NIMOTUZUMAB IN COMBINATION WITH CONCURRENT CHEMORADIOTHERAPY (CRT) IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Satouchi, M.
ANNALS OF ONCOLOGY, 2012, 23 : 57 - 57
[2] Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Barbaro, A.
Mienko, F.
Deng, L.
Ohri, N.
Halmos, B.
Perez-Soler, R.
Gucalp, R.
Bodner, W.
Cheng, H.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S906 - S907
[3] Real-World Evaluation of Consolidative Durvalumab in Locally Advanced Non-Small-Cell Lung Cancer Treated with Definitive Chemoradiation
Shaverdian, N.
Zhang, Z.
Lobaugh, S.
Deasy, J. O.
Offin, M.
Preeshagul, I.
Hellmann, M. D.
Chaft, J.
Shepherd, A. F.
Gelblum, D.
Lee, N.
Gomez, D.
Wu, A. J.
Rimner, A.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E531 - E531
[4] Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results
Verschueren, Marjon V.
Dijs, Talitha
Gulikers, Judith L.
van Veelen, Ard
Croes, Sander
Hendriks, Lizza E. L.
Smit, Adrianus A. J.
Bloem, Lourens T.
Egberts, Antoine C. G.
van de Garde, Ewoudt M. W.
Peters, Bas J. M.
IMMUNOTHERAPY, 2023, 15 (11) : 839 - 851
[5] Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
Noronha, Vanita
Talreja, Vikas T.
Patil, Vijay
Joshi, Amit
Menon, Nandini
Mahajan, Abhishek
Janu, Amit
Prabhash, Kumar
SOUTH ASIAN JOURNAL OF CANCER, 2020, 9 (03) : 180 - 182
[6] Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Jung, Hyun Ae
Noh, Jae Myoung
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Pyo, Hongryull
Ahn, Yong Chan
Park, Keunchil
LUNG CANCER, 2020, 146 : 23 - 29
[7] Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
Preti, Beatrice T. B.
Sanatani, Michael S.
Breadner, Daniel
Lakkunarajah, Suganija
Scott, Carolyn
Esmonde-White, Caroline
Mcarthur, Eric
Rodrigues, George
Chaudhary, Mitali
Mutsaers, Adam
Sachdeva, Robin
Vincent, Mark D.
CURRENT ONCOLOGY, 2023, 30 (08) : 7713 - 7721
[8] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Julian Taugner
Lukas Käsmann
Chukwuka Eze
Alexander Rühle
Amanda Tufman
Niels Reinmuth
Thomas Duell
Claus Belka
Farkhad Manapov
Investigational New Drugs, 2021, 39 : 1189 - 1196
[9] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Taugner, Julian
Kaesmann, Lukas
Eze, Chukwuka
Ruehle, Alexander
Tufman, Amanda
Reinmuth, Niels
Duell, Thomas
Belka, Claus
Manapov, Farkhad
INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1189 - 1196
[10] Chemotherapy and chemoradiotherapy of locally advanced non-small-cell lung cancer
Presselt, N
Wendt, T
Baum, RP
Treutler, D
Bonnet, R
Schmücking, M
Sammour, D
STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 : 34 - 34

← 1 2 3 4 5 →